| HOME >> MEDICINE >> TECHNOLOGY |
Selling, general and administrative expenses decreased to $65.0 million for the quarter ended December 31, 2010 from $84.2 million for the same period in 2009. The decrease primarily reflects lower incentive compensation costs and continued efforts to drive efficiencies in our cost structure.
Research and development expenses decreased to $35.0 million for the quarter ended December 31, 2010, compared to $50.2 million for the same period in 2009. The decrease primarily reflects lower incentive compensation costs and decreased expenses for BYDUREON pre-launch activities.
Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $63.1 million for the quarter ended December 31, 2010, compared to $75.4 million for the same period in 2009.
Non-GAAP operating income was $22.9 million for the quarter ended December 31, 2010, compared to non-GAAP operating loss of $17.0 million for the same period in 2009. GAAP net loss was $19.2 million, or $0.13 per share for the quarter ended December 31, 2010, compared to a loss of $50.3 million, or $0.35 per share for the same period in 2009. Net loss, excluding restructuring charges, was $11.9 million, or $0.08 per share for the quarter ended December 31, 2010, compared to a loss of $44.7 million, or $0.32 per share for the same period in 2009.
Year Ended December 31, 2010Total revenue for the year ended December 31, 2010 was $668.8 million. This includes net product sales of $651.1 million, consisting of $559.3 million for BYETTA sales in the U.S. and $91.8 million for SYMLIN. This compares to total revenue of $758.4 million for 2009, inclu
'/>"/>
| SOURCE Amylin Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |